Indications for Racecadotril Tablets
Racecadotril is indicated as symptomatic treatment for acute diarrhea in adults and children, particularly as an adjunct to oral rehydration therapy, and has specific guideline-supported use in Grade 1 immunotherapy-induced diarrhea in cancer patients.
Primary Indications
Acute Diarrhea (General Population)
Racecadotril functions as an antisecretory agent that inhibits neutral endopeptidase (NEP), thereby preventing the degradation of enkephalins. This mechanism reduces water and electrolyte secretion in the small intestine without affecting intestinal motility 1. The drug is effective in reducing:
- Duration of diarrheal illness
- Stool frequency and volume
- Associated symptoms like abdominal pain
Important distinction: Unlike loperamide, racecadotril does not slow intestinal transit, making it safer in certain infectious diarrhea scenarios 2.
Cancer-Related Diarrhea (Guideline-Supported)
The 2018 ESMO Clinical Practice Guidelines provide the most specific indication for racecadotril 3:
For immunotherapy-induced diarrhea:
- Grade 1 diarrhea: Racecadotril or loperamide as symptomatic treatment with oral rehydration [Level III, Grade A evidence] 3
- Used as first-line antidiarrheal agent alongside oral rehydration solutions
Critical caveat: The IDSA 2017 guidelines note that racecadotril "reduces stool volume but is not available in North America" 2, limiting its use geographically despite proven efficacy.
Mechanism and Clinical Advantages
Racecadotril works by:
- Inhibiting enkephalinase in the small bowel
- Allowing enkephalins to exhibit antisecretory effects
- Reducing water/electrolyte secretion without affecting motility 1
Key advantages over loperamide:
- No effect on intestinal transit time
- Lower risk of rebound constipation
- Better tolerability profile in comparative studies 4
- Can be used safely in infectious diarrhea without risk of toxic megacolon
Pediatric Use
Racecadotril has demonstrated efficacy in children with acute diarrhea 5, 6:
- Reduces duration of illness by approximately 28 hours compared to placebo
- Comparable safety profile to placebo
- Recommended as adjunct to oral rehydration solution
- Meta-analyses support its use with consistent benefit across multiple efficacy parameters
Contraindications and Limitations
Do not use racecadotril in:
- Patients requiring treatment for severe dehydration requiring IV therapy (rehydration must be addressed first)
- Grade 3-4 immunotherapy-induced diarrhea (requires corticosteroids, not antidiarrheals) 3
Geographic availability: Not available in North America despite guideline recommendations 2
Comparative Efficacy
Evidence shows racecadotril is:
- More effective than placebo for symptom duration and stool output 6, 4
- Similar efficacy to loperamide but with better tolerability 4
- More effective than Saccharomyces boulardii 4
- Less effective than octreotide in severe hospitalized cases requiring IV antibiotics 4
Bottom line: Racecadotril serves as a well-tolerated antisecretory agent for acute diarrhea across age groups, with specific guideline support for mild immunotherapy-induced diarrhea in cancer patients, though geographic availability limits its use in North America.